Experimental assessment of the specific activity of a new dosage form of angiolin in cataract modeling

Biological Markers and Guided Therapy Pub Date : 1900-01-01 DOI:10.12988/bmgt.2019.91013

I. Belenichev, L. Kucherenko, I. Mazur, R. Akopyan, E. A. Portnaya

{"title":"Experimental assessment of the specific activity of a new dosage form of angiolin in cataract modeling","authors":"I. Belenichev, L. Kucherenko, I. Mazur, R. Akopyan, E. A. Portnaya","doi":"10.12988/bmgt.2019.91013","DOIUrl":null,"url":null,"abstract":"Age-related cataract is currently the leading cause of incurable blindness in the world and the most common eye disease in people over 60 years. Among all ophthalmic diseases, cataract is about 65%. The following medicines are used to treat cataracts: Oftan Catachrom (Santen AO, Finland), Taufon (Farmak, OAO, Kiev, Ukraine.), Quinax (Alcon -Couvreur, Belgium), Vita-Iodurol (Excelvision AG for Novartis Pharma AG, France/Switzerland), Potassium iodide (OOO “UNIMED PHARMA”, Slovak Republic). Based on the foregoing, it is clear that the range of drugs for the treatment of cataracts is limited, and mainly consists of imported drugs. All of the above opens up new prospects for the creation of new ophthalmic medicines for expanding the range of domestic drugs, namely eye drops with wound healing, reparative, anti-inflammatory effects. Therefore, the aim of our work is to create a new ophthalmic drug based on the original substance Angiolin, which will exhibit anti-inflammatory, wound healing, reparative properties. cataract was reproduced on both eyes of 10 animals (20 eyes) by chemical induction of free radical oxidation of biopolymers of eye tissues according to the D.K. Buyan method, for which 30 μl of a sterile solution of dibromide diquat at a dose of 600 nmol was injected once into the vitreous body. Treatment began from 7 days, when the initial opacity of the lens was formed, and was carried out by instillation of drugs into the conjunctival cavity of the eyes 3 times a day. Results: the course administration of 1% Angiolin eye drops had a significant therapeutic effect in the conditions of chemical cataracts. The use of Angiolin drops reduced the lens opacity of the eye of experimental animals by 43,5%. Findings: 1% Angiolin eye drops ((S) -2,6-diaminohexanoic acid 3-methyl-1,2,4-triazolyl-5-thioacetate) as an active ingredient, exhibit significant anti-inflammatory, wound healing, reparative properties, and also have a high therapeutic effect in the treatment of cataracts.","PeriodicalId":150008,"journal":{"name":"Biological Markers and Guided Therapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biological Markers and Guided Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12988/bmgt.2019.91013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Age-related cataract is currently the leading cause of incurable blindness in the world and the most common eye disease in people over 60 years. Among all ophthalmic diseases, cataract is about 65%. The following medicines are used to treat cataracts: Oftan Catachrom (Santen AO, Finland), Taufon (Farmak, OAO, Kiev, Ukraine.), Quinax (Alcon -Couvreur, Belgium), Vita-Iodurol (Excelvision AG for Novartis Pharma AG, France/Switzerland), Potassium iodide (OOO “UNIMED PHARMA”, Slovak Republic). Based on the foregoing, it is clear that the range of drugs for the treatment of cataracts is limited, and mainly consists of imported drugs. All of the above opens up new prospects for the creation of new ophthalmic medicines for expanding the range of domestic drugs, namely eye drops with wound healing, reparative, anti-inflammatory effects. Therefore, the aim of our work is to create a new ophthalmic drug based on the original substance Angiolin, which will exhibit anti-inflammatory, wound healing, reparative properties. cataract was reproduced on both eyes of 10 animals (20 eyes) by chemical induction of free radical oxidation of biopolymers of eye tissues according to the D.K. Buyan method, for which 30 μl of a sterile solution of dibromide diquat at a dose of 600 nmol was injected once into the vitreous body. Treatment began from 7 days, when the initial opacity of the lens was formed, and was carried out by instillation of drugs into the conjunctival cavity of the eyes 3 times a day. Results: the course administration of 1% Angiolin eye drops had a significant therapeutic effect in the conditions of chemical cataracts. The use of Angiolin drops reduced the lens opacity of the eye of experimental animals by 43,5%. Findings: 1% Angiolin eye drops ((S) -2,6-diaminohexanoic acid 3-methyl-1,2,4-triazolyl-5-thioacetate) as an active ingredient, exhibit significant anti-inflammatory, wound healing, reparative properties, and also have a high therapeutic effect in the treatment of cataracts.

查看原文本刊更多论文

一种新剂型血管素在白内障建模中的比活性实验评价

老年性白内障是目前世界上无法治愈的失明的主要原因，也是60岁以上人群中最常见的眼病。在所有眼科疾病中，白内障约占65%。以下药物用于治疗白内障:Oftan Catachrom (Santen AO，芬兰)，Taufon (Farmak, OAO，乌克兰基辅)，Quinax (Alcon -Couvreur，比利时)，Vita-Iodurol (Excelvision AG for Novartis Pharma AG，法国/瑞士)，碘化钾(OOO“UNIMED Pharma”，斯洛伐克共和国)。综上所述，治疗白内障的药物范围是有限的，而且主要是进口药物。所有这些都为创造新的眼科药物开辟了新的前景，扩大了国产药物的范围，即具有伤口愈合，修复，抗炎作用的眼药水。因此，我们的工作目标是在原物质血管素的基础上研制一种具有抗炎、伤口愈合、修复功能的新型眼科药物。采用布扬(D.K. Buyan)方法，在玻璃体内注射剂量为600 nmol的双溴双喹特无菌溶液30 μl，化学诱导眼组织生物聚合物自由基氧化，使10只动物(20只眼)双眼再生白内障。治疗从晶状体最初混浊形成的第7天开始，通过每天3次在眼睛结膜腔内滴注药物进行。结果:1%血管素滴眼液治疗化学性白内障疗效显著。血管素滴剂的使用使实验动物的晶状体混浊率降低了43.5%。结果:1%血管素滴眼液((S) -2,6-二氨基己酸3-甲基-1,2,4-三唑基-5-硫乙酸酯)作为有效成分，具有显著的抗炎、伤口愈合、修复作用，对白内障的治疗也有较高的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biological Markers and Guided Therapy

自引率

0.00%

发文量